Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Journal of Medicinal Chemistry
|
August 14, 2020
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay
Thomas Knoepfel, Pierre Nimsgern, Sébastien Jacquier, et al.
Nature Chemical Biology
|
January 30, 2019
An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient
Jean Quancard, Theo Klein, Shan-Yu Fung, et al.
Journal of Medicinal Chemistry
|
November 3, 2020
Evolution of Novartis' Small Molecule Screening Deck Design
Ansgar Schuffenhauer, Nadine Schneider, Samuel Hintermann, et al.
ACS Medicinal Chemistry Letters
|
April 22, 2022
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an <i>In Vivo</i> Efficacious TLR7/8 Antagonist
Claudia Betschart, Michael Faller, Florence Zink, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 5, 2018
Discovery of 1-((6-Aminopyridin-3-yl)Methyl)-3-(4-Bromophenyl)Urea as a Potent, Irreversible Myeloperoxidase Inhibitor
Martin L Marro, Andrew W Patterson, Lac Lee, et al.
Nature Communications
|
September 7, 2023
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β
Ulrich Hommel, Konstanze Hurth, Jean-Michel Rondeau, et al.
Journal of Medicinal Chemistry
|
November 30, 2020
Discovery of Potent, Highly Selective, and <i>In Vivo</i> Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing
Carole Pissot Soldermann, Oliver Simic, Martin Renatus, et al.
ACS Chemical Biology
|
January 3, 2023
Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction
Jian Ding, Guo Li, Hejun Liu, et al.
Molecular Cancer Therapeutics
|
August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss, Flavia Adler, Alexandra Buhles, et al.
Journal of Medicinal Chemistry
|
May 10, 2024
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches
Anna Vulpetti, Jean-Michel Rondeau, Marie-Hélène Bellance, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Journal of Medicinal Chemistry
|
August 14, 2020
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay
Thomas Knoepfel, Pierre Nimsgern, Sébastien Jacquier, et al.
Nature Chemical Biology
|
January 30, 2019
An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient
Jean Quancard, Theo Klein, Shan-Yu Fung, et al.
Journal of Medicinal Chemistry
|
November 3, 2020
Evolution of Novartis' Small Molecule Screening Deck Design
Ansgar Schuffenhauer, Nadine Schneider, Samuel Hintermann, et al.
ACS Medicinal Chemistry Letters
|
April 22, 2022
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an <i>In Vivo</i> Efficacious TLR7/8 Antagonist
Claudia Betschart, Michael Faller, Florence Zink, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 5, 2018
Discovery of 1-((6-Aminopyridin-3-yl)Methyl)-3-(4-Bromophenyl)Urea as a Potent, Irreversible Myeloperoxidase Inhibitor
Martin L Marro, Andrew W Patterson, Lac Lee, et al.
Nature Communications
|
September 7, 2023
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β
Ulrich Hommel, Konstanze Hurth, Jean-Michel Rondeau, et al.
Journal of Medicinal Chemistry
|
November 30, 2020
Discovery of Potent, Highly Selective, and <i>In Vivo</i> Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing
Carole Pissot Soldermann, Oliver Simic, Martin Renatus, et al.
ACS Chemical Biology
|
January 3, 2023
Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction
Jian Ding, Guo Li, Hejun Liu, et al.
Molecular Cancer Therapeutics
|
August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss, Flavia Adler, Alexandra Buhles, et al.
Journal of Medicinal Chemistry
|
May 10, 2024
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches
Anna Vulpetti, Jean-Michel Rondeau, Marie-Hélène Bellance, et al.
Page
of 3